StoneX Group’s Processa Pharmaceuticals PCSA Stock Holding History

StoneX Group’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-11,437	Closed	-$29.6K	–	2133
2026 Q2	$29.6K	Buy	+11,437	New	+$29.6K	﹤0.01%	1273
2025 Q4	–	Sell	-758	Closed	-$3.64K	–	1169
2025 Q3	$3.64K	Buy	+758	New	+$4K	﹤0.01%	916

Other funds holding PCSA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

StoneX Group's PCSA Position: Q3 2026 in Review

StoneX Group sold out of Processa Pharmaceuticals (PCSA) in Q3 2026, closing a stake of 11,437 shares — an estimated $29.6K sold.

StoneX Group first reported a position in PCSA in Q3 2025 and held it in 2 quarters. The position peaked at $29.6K in Q2 2026. 9 funds tracked by Wall St. Rank hold PCSA as of Q3 2026.

StoneX Group reported no remaining Processa Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
StoneX Group sold 11,437 Processa Pharmaceuticals shares in Q3 2026, an estimated $29.6K.
StoneX Group first reported a position in Processa Pharmaceuticals in Q3 2025 and held it in 2 quarters.
StoneX Group's Processa Pharmaceuticals position peaked at $29.6K in Q2 2026.
9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.